TrialPath
Heart failure · Phoenix

Heart failure clinical trials in Phoenix

20 recruiting heart failure studies within range of Phoenix. Click any trial for full eligibility criteria and contact info.

Left vs Left Randomized Clinical Trial

Recruiting

The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated \>40% pacing who are already receiving current standard heart failure pharmacological therapy.

PhaseNA
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 70 more
SponsorBaylor College of Medicine
▾Tap for details
Apply

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404 · Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children
Recruiting

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Phase—
TypeObservational
Age0 Years – 20 Years
WherePhoenix, Arizona, United States + 51 more
SponsorDuke University
▾Tap for details
Apply

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950 · Heart Failure
Recruiting

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).

PhasePhase 3
TypeInterventional
Age18 Years
WhereFairhope, Alabama, United States + 175 more
SponsorColorado Prevention Center
▾Tap for details
Apply

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001 · Obesity, Heart Failure
Recruiting

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAlexander City, Alabama, United States + 837 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Recruiting

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

PhasePhase 3
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 355 more
SponsorColorado Prevention Center
▾Tap for details
Apply

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Recruiting

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

PhasePhase 3
TypeInterventional
Age18 Years – 99 Years
WhereBirmingham, Alabama, United States + 685 more
SponsorAmgen
▾Tap for details
Apply

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

NCT04905160 · Heart Failure, ADHF, Acute MI
Recruiting

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States
SponsorAventyn, Inc.
▾Tap for details
Apply

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297 · Neutropenia
Recruiting

The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.

PhasePhase 3
TypeInterventional
Age12 Years
WherePhoenix, Arizona, United States + 114 more
SponsorX4 Pharmaceuticals
▾Tap for details
Apply

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195 · Heart Failure, Heart Diseases, Cardiovascular Diseases
Recruiting

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 69 more
SponsorAbbott Medical Devices
▾Tap for details
Apply

BiVACOR® Total Artificial Heart Early Feasibility Study

NCT06174103 · Heart Failure, Biventricular Failure
Recruiting

The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVACOR TAH System in study subjects.

PhaseNA
TypeInterventional
Age18 Years – 70 Years
WherePhoenix, Arizona, United States + 3 more
SponsorBiVACOR Inc.
▾Tap for details
Apply

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851 · Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature
Recruiting

This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \<18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. This trial will be conducted in the United States, France, Germany, Italy, Romania, Spain and South Korea.

PhasePhase 3
TypeInterventional
Age2 Years – 17 Years
WherePhoenix, Arizona, United States + 55 more
SponsorAscendis Pharma A/S
▾Tap for details
Apply

CCM OPEN HF Registry

NCT07112924 · Heart Failure
Recruiting

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Phase—
TypeObservational
Age18 Years
WhereMesa, Arizona, United States + 29 more
SponsorImpulse Dynamics
▾Tap for details
Apply

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Recruiting

This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT). 2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

PhaseNA
TypeInterventional
Age18 Years
WhereHuntsville, Alabama, United States + 42 more
SponsorBoston Scientific Corporation
▾Tap for details
Apply

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Recruiting

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

PhaseNA
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 25 more
SponsorAxon Therapies, Inc.
▾Tap for details
Apply

His-Bundle Corrective Pacing in Heart Failure

NCT05265520 · Right Bundle-Branch Block, Heart Failure, His-bundle Pacing
Recruiting

The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 13 more
SponsorUniversity of Rochester
▾Tap for details
Apply

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Recruiting

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Phase—
TypeObservational
AgeAny
WhereBirmingham, Alabama, United States + 78 more
SponsorChildren's Oncology Group
▾Tap for details

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06777368 · Aortic Stenosis
Recruiting

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).

Phase—
TypeObservational
Age18 Years – 105 Years
WhereBirmingham, Alabama, United States + 70 more
SponsorMedtronic Cardiovascular
▾Tap for details
Apply

ELEVATE-HFpEF Clinical Study

Recruiting

ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

PhaseNA
TypeInterventional
Age40 Years
WherePhoenix, Arizona, United States + 54 more
SponsorMedtronic Cardiac Rhythm and Heart Failure
▾Tap for details
Apply

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

NCT07403669 · Acute MI, Heart Failure, Diabetes Mellitus
Recruiting

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

PhaseNA
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 4 more
SponsorAventyn, Inc.
▾Tap for details
Apply

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

NCT03142152 · Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency
Recruiting

The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

PhaseNA
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 91 more
SponsorCardiac Dimensions, Inc.
▾Tap for details
Apply